Hydrochloric Acid

Hydrochloric Acid

SCHEMBL953664

Cl.Cl.O.O.O.O.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0812324-B1 AQUEOUS SPECTINOMYCIN BORATE SOLUTIONS MERIAL SAS (FR) 2000-05-10 EP claimed
EP-0812324-A1 AQUEOUS SPECTINOMYCIN BORATE SOLUTIONS Mérial (FR) 1997-12-17 EP claimed
US-5556879-A STABILITY AT HIGH CONCENTRATION RHONE MERIEUX, INC. (US) 1996-09-17 US claimed
WO-1996026945-A1 AQUEOUS SPECTINOMYCIN BORATE SOLUTIONS MERIAL (FR) 1996-09-06 WO claimed
US-4312884-A Treatment of herpes simplex SOICHET SAMUEL 1982-01-26 US claimed
EP-4626866-A1 NOVEL TRILACICLIB INTERMEDIATES, METHOD OF PREPARATION AND USE THEREOF Assia Chemical Industries Ltd. (IL) 2025-10-08 EP disclosed
US-20250144067-A1 PERSONALIZED STARVATION THERAPY FOR CANCER FAETH THERAPEUTICS, INC. 2025-05-08 US disclosed
WO-2024116069-A1 NOVEL TRILACICLIB INTERMEDIATES, METHOD OF PREPARATION AND USE THEREOF ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2024-06-06 WO disclosed
US-11779905-B2 Catalyst compositions and process for direct production of hydrogen cyanide in an acrylonitrile reactor feed stream ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2023-10-10 US disclosed
EP-3259366-B1 MICROBIAL MICROFLUIDIC BIOSENSOR UNIV CALIFORNIA (US) 2022-04-20 EP disclosed
US-20210146339-A1 CATALYST COMPOSITIONS AND PROCESS FOR DIRECT PRODUCTION OF HYDROGEN CYANIDE IN AN ACRYLONITRILE REACTOR FEED STREAM ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2021-05-20 US disclosed
EP-3744418-A1 CATALYST COMPOSITIONS AND PROCESS FOR DIRECT PRODUCTION OF HYDROGEN CYANIDE IN AN ACRYLONITRILE REACTOR FEED STREAM Ascend Performance Materials Operations LLC (US) 2020-12-02 EP disclosed
WO-1998025901-A1 INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI (FR) 1998-06-18 WO disclosed
US-5716965-A Substituted 3-aminoquinuclidines PFIZER INC. (US) 1998-02-10 US disclosed
EP-0812324-A1 AQUEOUS SPECTINOMYCIN BORATE SOLUTIONS Mérial (FR) 1997-12-17 EP disclosed
US-5556879-A STABILITY AT HIGH CONCENTRATION RHONE MERIEUX, INC. (US) 1996-09-17 US disclosed
WO-1996026945-A1 AQUEOUS SPECTINOMYCIN BORATE SOLUTIONS MERIAL (FR) 1996-09-06 WO disclosed
EP-0585328-A1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER INC. (US) 1994-03-09 EP disclosed
WO-1992020676-A1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER INC. (US) 1992-11-26 WO disclosed
US-4312884-A Treatment of herpes simplex SOICHET SAMUEL 1982-01-26 US disclosed